

3rd Immunonutrition Workshop, 21–24 October 2009, Girona, Spain

## No effect of vitamin D supplementation on serum fibrinogen concentrations in adults aged ≥64 years

M. S. Barnes<sup>1</sup>, L. K. Forsythe<sup>1</sup>, G. Horigan<sup>1</sup>, M. P. Bonham<sup>1</sup>, E. M. Duffy<sup>1</sup>, T. R. Hill<sup>2</sup>, A. J. Lucey<sup>2</sup>, K. D. Cashman<sup>2</sup>, M. Kiely<sup>2</sup>, J. J. Strain<sup>1</sup> and J. M. W. Wallace<sup>1</sup>

<sup>1</sup>Northern Ireland Centre for Food & Health (NICHE), University of Ulster, Coleraine BT52 1SA and <sup>2</sup>Department of Food and Nutritional Sciences, University College Cork, Republic of Ireland

High serum concentration of the acute phase protein fibrinogen is associated with tissue inflammation and is an independent risk factor for cardiovascular disease (CVD). Low vitamin D status is associated with an increased risk of CVD and the active form of the vitamin, 1,25-dihydroxyvitamin D<sub>3</sub>, is a potent immunomodulator. Furthermore, vitamin D supplementation has been shown to reduce serum concentrations of inflammatory markers such as C-reactive protein in vitamin D deficient individuals. The aim of this study was to assess the effect of vitamin D supplementation on serum fibrinogen concentrations in a group of apparently healthy adults aged ≥ 64 years recruited in Cork and Coleraine.

A total of 202 individuals (males, *n* = 81; females, *n* = 121) were randomly assigned to receive either 5, 10 or 15 µg vitamin D<sub>3</sub>/d or placebo for 22 weeks. Serum vitamin D status (25-hydroxyvitamin D (25(OH)D)) and fibrinogen concentrations were measured at baseline and post intervention using commercially available ELISA kits.

Vitamin D status did not significantly correlate with serum fibrinogen concentrations at baseline or post intervention. One-way analysis of covariance (adjusted for age, sex, centre, body mass index and baseline concentrations) revealed that while vitamin D supplementation significantly increased vitamin D status, it did not alter fibrinogen concentrations.

	Treatment group (µg vitamin D <sub>3</sub> /d <sup>†</sup> )				<i>P</i> <sup>†</sup>
	Placebo ( <i>n</i> = 54)	5 µg/d ( <i>n</i> = 48)	10 µg/d ( <i>n</i> = 52)	15 µg/d ( <i>n</i> = 48)	
25(OH)D (nmol/l)					
Pre	59.07 (43.37, 78.64)	51.84 (40.28, 71.34)	55.53 (43.00, 72.26)	55.09 (39.39, 70.82)	
Post	42.59 (27.82, 55.86) <sup>a</sup>	53.19 (45.57, 68.73) <sup>b</sup>	70.32 (57.98, 81.81) <sup>cd</sup>	73.86 (61.87, 90.20) <sup>cd</sup>	<0.0001
Fibrinogen (g/l)					
Pre	1.86 (1.25, 2.91)	2.12 (1.44, 3.54)	1.78 (1.25, 2.85)	2.22 (1.31, 3.08)	
Post	2.19 (1.60, 3.07)	2.10 (1.47, 3.79)	2.02 (1.40, 2.81)	2.18 (1.74, 3.20)	0.889

25(OH)D, 25-hydroxyvitamin D.

\* Values are median (IQR).

† Effect of treatment assessed on log transformed data by ANCOVA. Different superscript letters denote significant differences between treatment groups (ANOVA).

In conclusion, vitamin D supplementation had a significant dose-response effect on vitamin D status, but did not affect serum concentrations of the inflammatory marker fibrinogen in healthy older adults. These findings concur with previous research in vitamin D deficient adults. However, it has been suggested that 25(OH)D concentrations >100 nmol/l may be required for modulation of immune responses; concentrations higher than those observed in the current study, even after vitamin D supplementation.

This work was supported by the UK Food Standards Agency.